Package leaflet: Information for the user

Similar documents
Package leaflet: Information for the user

Package leaflet: Information for the patient. Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets Aliskiren

Package leaflet: Information for the user

Package leaflet: Information for the patient. Briviact 75 mg film-coated tablets. Briviact 25 mg film-coated tablets

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1

Package leaflet: Information for the patient Komboglyze 2.5 mg/1,000 mg film-coated tablets saxagliptin/metformin

Package leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine

Package leaflet: Information for the user. Epclusa 400 mg/100 mg film-coated tablets sofosbuvir/velpatasvir

Package leaflet: information for the user. Opsumit 10 mg film-coated tablets macitentan

Package leaflet: Information for the user. Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride

Package leaflet: Information for the patient. Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib

Package leaflet: Information for the patient

Package leaflet: Information for the user. Inovelon 400 mg film-coated tablets. Rufinamide

Package leaflet: Information for the patient. Daxas 500 micrograms film-coated tablets Roflumilast

Package leaflet: Information for the user. Renvela 800 mg film-coated tablets sevelamer carbonate

Package leaflet: Information for the patient. Onglyza 2.5 mg film-coated tablets Onglyza 5 mg film-coated tablets Saxagliptin

Package leaflet: Information for the user. Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate

Package leaflet: Information for the patient. Zeffix 100 mg film-coated tablets lamivudine

Package leaflet: Information for the user

Package leaflet: Information for the user. Raxone 150 mg film-coated tablets idebenone

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

B. PACKAGE LEAFLET 1

Package leaflet: Information for the patient

Package leaflet: information for the user. amlodipine/valsartan

Package leaflet: Information for the patient

Package leaflet: Information for the user. Edarbi 20 mg tablets Edarbi 40 mg tablets Edarbi 80 mg tablets Azilsartan medoxomil

Package leaflet: Information for the user. Zometa 4 mg/100 ml solution for infusion Zoledronic acid

Package leaflet: Information for the patient. Briviact 10mg/ml solution for injection/infusion brivaracetam

Package leaflet: Information for the user

Package Leaflet: Information for the user. Perjeta 420 mg concentrate for solution for infusion pertuzumab

Zofran tablets contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the patient. Integrilin 2 mg/ml solution for injection eptifibatide

Package leaflet: Information for the user

Package leaflet: Information for the user. Tracleer 62.5 mg film-coated tablets Bosentan

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xolair 75 mg solution for injection Xolair 150 mg solution for injection Omalizumab

Package leaflet: Information for the patient. NINLARO 2.3 mg hard capsules NINLARO 3 mg hard capsules NINLARO 4 mg hard capsules ixazomib

Package leaflet: Information for the user. Samsca 7.5 mg tablets Samsca 15 mg tablets Samsca 30 mg tablets tolvaptan

PACKAGE LEAFLET: INFORMATION FOR THE USER

BONVIVA 150 mg film-coated tablets

Package leaflet: Information for the patient. Cotellic 20 mg film-coated tablets cobimetinib

Package leaflet: Information for the user. Fluvastatin

Package leaflet: Information for the patient

Package leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin

Package leaflet: Information for the user. Spinraza 12 mg solution for injection. nusinersen

B. PACKAGE LEAFLET 18

Package leaflet: Information for the user. Lycimor 300 mg Hard Capsules Lymecycline (equivalent to 300mg of tetracycline base)

B. PACKAGE LEAFLET 25

Package leaflet: Information for the user. Clopidogrel Mylan 75 mg film-coated tablets clopidogrel

Package leaflet: Information for the user. Lysodren 500 mg tablets Mitotane

Package leaflet: Information for the user. STAYVEER 62.5 mg film-coated tablets Bosentan

Package leaflet: Information for the user Esbriet 267 mg hard capsules Pirfenidone

If you have any questions about how Letrozole Tablets works or why this medicine has been prescribed for you, ask your doctor.

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine

Package leaflet: Information for the patient. Valotix 500 mg Film-Coated Tablets Valaciclovir

Package leaflet: Information for the patient. Viread 245 mg film-coated tablets Tenofovir disoproxil

Package leaflet: Information for the user

Package leaflet: Information for the user. Famvir 125, 250 and 500 mg film-coated tablets famciclovir

Package leaflet: Information for the patient. Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets ruxolitinib

Package leaflet: Information for the patient. Memantine Mylan 10 mg film-coated tablets memantine hydrochloride

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER. CIALIS 10 mg film-coated tablets tadalafil

Package leaflet: Information for the patient Komboglyze 2.5 mg/1,000 mg film-coated tablets saxagliptin/metformin

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin

Package leaflet: Information for the user Arixtra 1.5 mg/0.3 ml solution for injection fondaparinux sodium

Package leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa

Package leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine

Package leaflet: Information for the patient. Selincro 18 mg film-coated tablets nalmefene

PACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine

Package leaflet: Information for the patient. Exviera 250 mg film-coated tablets dasabuvir

Package leaflet: Information for the user. Irprestan 150 mg film-coated tablets. Irprestan 300 mg film-coated tablets irbesartan

Package Leaflet: Information for the User Zofran tablets 4 mg and 8 mg ondansetron (as hydrochloride dihydrate)

1. What Faslodex is and what it is used for

Package leaflet: Information for the patient. Symkevi 100 mg/150 mg film-coated tablets tezacaftor/ivacaftor

Pravat 40 mg tablets. Pravastatin sodium

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil

Elements for a public summary

Package leaflet: Information for the patient. Tecfidera 240 mg gastro-resistant hard capsules. dimethyl fumarate

leflunomide Package leaflet: Information for the user Leflunomide Winthrop 20 mg film-coated tablets

Package leaflet: Information for the user

Package leaflet: Information for the patient. CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab

Package leaflet: information for the user

Package leaflet: Information for the user. CIALIS 5 mg film-coated tablets tadalafil

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR

Package leaflet: Information for the patient. Vimpat 150 mg film-coated tablets. Vimpat 100 mg film-coated tablets

Package leaflet: Information for the patient. Valsartan 320 mg Film-coated Tablets valsartan

Package leaflet: Information for the user. CIALIS 20 mg film-coated tablets tadalafil

Package leaflet: Information for the patient. SIRTURO 100 mg tablets Bedaquiline

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate)

Package leaflet: Information for the user. Epivir 150 mg film-coated tablets lamivudine

Package Leaflet: Information for the user

Package leaflet: Information for the patient. Vimpat 150 mg film-coated tablets. Vimpat 100 mg film-coated tablets

2 What you need to know before you use Zofran Suppositories

Transcription:

Package leaflet: Information for the user EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets Deferasirox This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed only for you or your child. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What EXJADE is and what it is used for 2. What you need to know before you take EXJADE 3. How to take EXJADE 4. Possible side effects 5. How to store EXJADE 6. Contents of the pack and other information 1. What EXJADE is and what it is used for What EXJADE is EXJADE contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools. What EXJADE is used for Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called iron chelators are used to remove the excess iron and reduce the risk of it causing organ damage. EXJADE is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older. EXJADE is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.

EXJADE is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent. 2. What you need to know before you take EXJADE Do not take EXJADE - if you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section 6). If this applies to you, tell your doctor before taking EXJADE. If you think you may be allergic, ask your doctor for advice. - if you have moderate or severe kidney disease. - if you are currently taking any other iron chelator medicines. EXJADE is not recommended - if you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer. Warnings and precautions Talk to your doctor or pharmacist before taking EXJADE: - if you have a kidney or liver problem. - if you have a cardiac problem due to iron overload. - if you notice a marked decrease in your urine output (sign of kidney problem). - if you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction, see also section 4 Possible side effects ). - if you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction, see also section 4 Possible side effects ). - if you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems). - if you vomit blood and/or have black stools. - if you experience frequent abdominal pain, particularly after eating or taking EXJADE. - if you experience frequent heartburn. - if you have a low level of platelets or white blood cells in your blood test. - if you have blurred vision - if you have diarrhoea or vomiting. If any of these apply to you, tell your doctor straight away. Monitoring your EXJADE treatment You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well EXJADE is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). Your doctor may require you to undergo a kidney biopsy, if he/she suspects significant kidney damage. You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of EXJADE most suitable for you and will also use these tests to decide when you should stop taking EXJADE. Your eyesight and hearing will be tested each year during treatment as a precautionary measure.

Other medicines and EXJADE Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular: - other iron chelators, which must not be taken with EXJADE, - antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as EXJADE, - ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis), - simvastatin (used to lower cholesterol), - certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids), - oral bisphosphonates (used to treat osteoporosis), - anticoagulant medicines (used to prevent or treat blood clotting), - hormonal contraceptive agents (birth control medicines), - bepridil, ergotamine (used for heart problems and migraines), - repaglinide (used to treat diabetes), - rifampicin (used to treat tuberculosis), - phenytoin, phenobarbital, carbamazepine (used to treat epilepsy), - ritonavir (used in the treatment of HIV infection), - paclitaxel (used in cancer treatment), - theophylline (used to treat respiratory diseases such as asthma), - clozapine (used to treat psychiatric disorders such as schizophrenia), - tizanidine (used as a muscle relaxant), - cholestyramine (used to lower cholesterol levels in the blood). Additional tests may be required to monitor the blood levels of some of these medicines. Older people (age 65 years and over) EXJADE can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients. They should be monitored closely by their doctor for side effects that may require a dose adjustment. Children and adolescents EXJADE can be used in children and adolescents receiving regular blood transfusions aged 2 years and over and in children and adolescents not receiving regular blood transfusions aged 10 years and over. As the patient grows the doctor will adjust the dose. EXJADE is not recommended for children aged under 2 years. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. EXJADE is not recommended during pregnancy unless clearly necessary. If you are currently using an oral contraceptive or using a patch contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom), as EXJADE may reduce the effectiveness of oral and patch contraceptives. Breast-feeding is not recommended during treatment with EXJADE. Driving and using machines If you feel dizzy after taking EXJADE, do not drive or operate any tools or machines until you are feeling

normal again. 3. How to take EXJADE Treatment with EXJADE will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. How much EXJADE to take The dose of EXJADE is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day. The usual daily dose for EXJADE film-coated tablets at the start of the treatment for patients receiving regular blood transfusions is 14 mg per kilogram body weight. A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs. The usual daily dose for EXJADE film-coated tablets at the start of the treatment for patients not receiving regular blood transfusions is 7 mg per kilogram body weight. Depending on how you respond to treatment, your doctor may later adjust your treatment to a higher or lower dose. The maximum recommended daily dose for EXJADE film-coated tablets is: 28 mg per kilogram body weight for patients receiving regular blood transfusions, 14 mg per kilogram body weight for adult patients not receiving regular blood transfusions, 7 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions. Deferasirox also comes as dispersible tablets. If you are switching from the dispersible tablets to these film-coated tablets, you will need an adjustment of the dose. When to take EXJADE Take EXJADE once a day, every day, at about the same time each day with some water. Take EXJADE film-coated tablets either on an empty stomach or with a light meal. Taking EXJADE at the same time each day will also help you remember when to take your tablets. For patients who are unable to swallow whole tablets, EXJADE film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple). The food should be immediately and completely consumed. Do not store it for future use. How long to take EXJADE Continue taking EXJADE every day for as long as your doctor tells you. This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect (see also section 2: Monitoring your EXJADE treatment ). If you have questions about how long to take EXJADE, talk to your doctor. If you take more EXJADE than you should If you have taken too much EXJADE, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show them the pack of tablets. Medical treatment may be necessary.

If you forget to take EXJADE If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s). If you stop taking EXJADE Do not stop taking EXJADE unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section How long to take EXJADE ). 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment. Some side effects could be serious and need immediate medical attention. These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people). If you get a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction), If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes, (signs of severe skin reactions), If you notice a marked decrease in your urine output (sign of kidney problem), If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems), If you vomit blood and/or have black stools, If you experience frequent abdominal pain, particularly after eating or taking EXJADE, If you experience frequent heartburn, If you experience partial loss of vision, If you experience severe upper stomach pain (pancreatitis), stop taking this medicine and tell your doctor straight away. Some side effects could become serious. These side effects are uncommon. If you get blurred or cloudy eyesight, If you get reduced hearing, tell your doctor as soon as possible. Other side effects Very common (may affect more than 1 in 10 people) Disturbance in kidney function tests. Common (may affect up to 1 in 10 people) Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating, constipation, indigestion Rash Headache Disturbance in liver function tests Itching

Disturbance in urine test (protein in the urine) If any of these affects you severely, tell your doctor. Uncommon (may affect up to 1 in 100 people) Dizziness Fever Sore throat Swelling of arms or legs Change in the colour of the skin Anxiety Sleep disorder Tiredness If any of these affects you severely, tell your doctor. Frequency not known (cannot be estimated from the available data). A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated), in the number of white blood cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia) Hair loss Kidney stones Low urine output Tear in stomach or intestine wall that can be painful and cause nausea Severe upper stomach pain (pancreatitis) Abnormal level of acid in blood Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine. United Kingdom Ireland Malta Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store HPRA Pharmacovigilance Earlsfort Terrace IRL - Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.hpra.ie e-mail: medsafety@hpra.ie ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal 5. How to store EXJADE Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month. Do not use any pack that is damaged or shows signs of tampering. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. Contents of the pack and other information What EXJADE contains The active substance is deferasirox. Each film-coated tablet of EXJADE 90 mg contains 90 mg deferasirox. Each film-coated tablet of EXJADE 180 mg contains 180 mg deferasirox. Each film-coated tablet of EXJADE 360 mg contains 360 mg deferasirox. The other ingredients are microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica and poloxamer. The tablet coating material contains: hypromellose; titanium dioxide (E171); macrogol (4000); talc; indigo carmine aluminium lake (E132). What EXJADE looks like and contents of the pack EXJADE is supplied as film-coated tablets. The film-coated tablets are ovaloid and biconvex. EXJADE 90 mg film-coated tablets are light blue and stamped 90 on one side and NVR on the other. EXJADE 180 mg film-coated tablets are medium blue and stamped 180 on one side and NVR on the other. EXJADE 360 mg film-coated tablets are dark blue and stamped 360 on one side and NVR on the other. Each blister pack contains 30 or 90 film-coated tablets. The multipacks contain 300 (10 packs of 30) film-coated tablets. Not all pack sizes or strengths may be available in your country. Marketing Authorisation Holder Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR United Kingdom Manufacturer Novartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 Lietuva Tel: +370 5 269 16 50

България Novartis Bulgaria EOOD Тел.: +359 2 489 98 28 Česká republika Novartis s.r.o. Tel: +420 225 775 111 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 Eesti Tel: +372 66 30 810 Ελλάδα Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 Ísland Vistor hf. Sími: +354 535 7000 Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Κύπρος Τηλ: +357 22 690 690 Luxembourg/Luxemburg Novartis Pharma N.V Tél/Tel: +32 2 246 16 11 Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 Malta Tel: +356 2122 2872 Nederland Novartis Pharma B.V. Tel: +31 26 37 82 555 Norge Novartis Norge AS Tlf: +47 23 05 20 00 Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 Slovenija Tel: +386 1 300 75 50 Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 Sverige Novartis Sverige AB Tel: +46 8 732 32 00

Latvija SIA Novartis Baltics Tel: +371 67 887 070 United Kingdom Novartis Pharmaceuticals UK Ltd. Tel: +44 1276 698370 This leaflet was last revised in 11/2017 Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu